US Tariffs on Pharmaceutical Products from Indonesia — 10% (2026)
Tariff Rate Breakdown
Indonesia is a significant source of pharmaceutical products imports into the United States, with approximately $38B in total bilateral trade.
Following the Supreme Court's landmark February 20, 2026 decision striking down IEEPA tariffs, imports of pharmaceutical products from Indonesia are now subject to a 10% tariff under Section 122 of the Trade Act of 1974, effective February 24, 2026.
This 10% rate has a built-in expiration: Section 122 limits presidential tariff authority to 150 days, meaning the tariff expires approximately July 24, 2026 without congressional renewal.
Pharmaceutical Products (HTS Chapter 30) generally enter duty-free at the MFN level, with the Section 122 tariff as the primary duty. No additional Section 232 or Section 301 surcharges apply to most products in this category from Indonesia.
Key products in HTS Chapter 30 imported from Indonesia include Vaccines, Antibiotics, Insulin, Bandages, Diagnostic reagents, and Blood products.
Common Products in Chapter 30
Calculate Your Import Duty
Use our tariff calculator to estimate the exact duty on your pharmaceutical products imports from Indonesia.
Open Tariff CalculatorFrequently Asked Questions
What is the current tariff rate on pharmaceutical products from Indonesia?
Will the tariff on pharmaceutical products from Indonesia change?
How did the Supreme Court ruling affect pharmaceutical products imports from Indonesia?
Pharmaceutical Products Tariffs from Other Countries
Other Product Categories from Indonesia
Specific HTS Codes in Chapter 30
Related Pages
Tariff rates change fast. Stay ahead.
Free alerts when US import tariff rates change. Join importers and trade professionals who stay informed.
No spam. Unsubscribe anytime.